Targeting critical regions in genomic DNA with AT-specific anticancer drugs.
Cellular DNA is not a uniform target for DNA-reactive drugs. At the nucleotide level, drugs recognize and bind short motifs of a few base pairs. The location of drug adducts at the genomic level depends on how these short motifs are distributed in larger domains. This aspect, referred to as region specificity, may be critical for the biological outcome of drug action. Recent studies demonstrated that certain minor groove binding (MGB) drugs, such as bizelesin, produce region-specific lesions in cellular DNA. Bizelesin binds mainly T(A/T)(4)A sites, which are on average scarce, but occasionally cluster in distinct minisatellite regions (200-1000 bp of approximately 85-100% AT), herein referred to as AT islands. Bizelesin-targeted AT islands are likely to function as strong matrix attachment regions (MARs), domains that organize DNA loops on the nuclear matrix. Distortion of MAR-like AT islands may be a basis for the observed inhibition of new replicon initiation and the extreme lethality of bizelesin adducts (<10 adducts/cell for cell growth inhibition). Hence, long AT-islands represent a novel class of critical targets for anticancer drugs. The AT island paradigm illustrates the potential of the concept of regional targeting as an essential component of the rational design of new sequence-specific DNA-reactive drugs.
Woynarowski
Jan M
JM
Cancer Therapy and Research Center, Institute for Drug Development, University of Texas Health Science Center at San Antonio, 14960 Omicron Drive, San Antonio, TX 78245, USA. jmw1@saci.org
D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology*; D001483:Base Sequence; D001572:Benzofurans; D001665:Binding Sites; D003509:Cyclohexanecarboxylic Acids / Q000737:chemistry / Q000494:pharmacology; D053138:Cyclohexenes; D004249:DNA Damage; D004273:DNA, Neoplasm / Q000737:chemistry / Q000187:drug effects* / Q000235:genetics; D004214:Distamycins / Q000737:chemistry / Q000494:pharmacology; D015195:Drug Design; D000080890:Duocarmycins; D015894:Genome, Human; D006801:Humans; D007211:Indoles / Q000737:chemistry / Q000494:pharmacology; D009588:Nitrogen Mustard Compounds / Q000737:chemistry / Q000494:pharmacology; D020080:Tandem Repeat Sequences; D014407:Tumor Cells, Cultured; D014508:Urea / Q000031:analogs & derivatives / Q000737:chemistry / Q000494:pharmacology
D000970:Antineoplastic Agents; D001572:Benzofurans; D003509:Cyclohexanecarboxylic Acids; D053138:Cyclohexenes; D004273:DNA, Neoplasm; D004214:Distamycins; D000080890:Duocarmycins; D007211:Indoles; D009588:Nitrogen Mustard Compounds; C060090:adozelesin; C066900:tallimustine; D014508:Urea; C072257:bizelesin